Skip to main content

Drug Effect

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

GEROPHARM
GEROPHARMRussia - Moscow
1 program
1
GP404141Phase 31 trial
Active Trials
NCT06497036Active Not Recruiting160Est. Mar 2028
Young BioPharma
Young BioPharmaMA - Lowell
1 program
EchocardiographyN/A1 trial
Active Trials
NCT03830814Completed100Est. Jul 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
GEROPHARMGP404141
Young BioPharmaEchocardiography

Clinical Trials (2)

Total enrollment: 260 patients across 2 trials

Study of Efficacy, Safety and Immunogenicity of GP40141 (GEROPHARM, Russia) in Patients With Immune Thrombocytopenia

Start: Apr 2023Est. completion: Mar 2028160 patients
Phase 3Active Not Recruiting

The Effects of Sacubitril/Valsartan on the Heart Functions

Start: Jan 2017Est. completion: Jul 2018100 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.